Vyant Bio (VYNT) reported Q1 EPS from continuing operations of ($0.15), versus the consensus of ($0.16). Revenue for the quarter came in at $303 thousand versus the consensus estimate of $300 thousand.
Cash and cash equivalents totaled $16.4 million as of March 31, 2022.